About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 690571, 10 pages
http://dx.doi.org/10.1155/2012/690571
Review Article

T Cells in Gastric Cancer: Friends or Foes

1Patologia Medica, Dipartimento de Biomedicina, Azienda Ospedaliera Universitaria Careggi, Largo Brambilla 3, 50134 Firenze, Italy
2Department of Internal Medicine, University of Florence, Florence 50134, Italy
3Department of Medical and Surgical Critical Care, University of Florence, Florence 50134, Italy

Received 27 January 2012; Revised 15 March 2012; Accepted 27 March 2012

Academic Editor: Nejat Egilmez

Copyright © 2012 Amedeo Amedei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Ezzati, S. J. Henley, A. D. Lopez, and M. J. Thun, “Role of smoking in global and regional cancer epidemiology: current patterns and data needs,” International Journal of Cancer, vol. 116, no. 6, pp. 963–971, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. D. M. Parkin, “The global health burden of infection-associated cancers in the year 2002,” International Journal of Cancer, vol. 118, no. 12, pp. 3030–3044, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Parsonnet, G. D. Friedman, D. P. Vandersteen et al., “Helicobacter pylori infection and the risk of gastric carcinoma,” New England Journal of Medicine, vol. 325, no. 16, pp. 1127–1131, 1991. View at Scopus
  4. P. Correa, “Bacterial infections as a cause of cancer,” Journal of the National Cancer Institute, vol. 95, no. 7, p. E3, 2003. View at Scopus
  5. R. M. Peek Jr. and M. J. Blaser, “Helicobacter pylori and gastrointestinal tract adenocarcinomas,” Nature Reviews Cancer, vol. 2, no. 1, pp. 28–37, 2002. View at Scopus
  6. E. M. El-Omar, M. Carrington, W. H. Chow et al., “The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer,” Nature, vol. 412, no. 6842, p. 99, 2001. View at Scopus
  7. M. M. D'Elios, B. J. Appelmelk, A. Amedei, M. P. Bergman, and G. Del Prete, “Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry,” Trends in Molecular Medicine, vol. 10, no. 7, pp. 316–323, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” The Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. H. F. Dvorak, “Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing,” New England Journal of Medicine, vol. 315, no. 26, pp. 1650–1659, 1986. View at Scopus
  10. M. M. D'Elios, A. Amedei, and G. Del Prete, “Helicobacter pylori antigen-specific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma,” Microbes and Infection, vol. 5, no. 8, pp. 723–730, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Ekbom, “Risk of cancer in ulcerative colitis,” Journal of Gastrointestinal Surgery, vol. 2, no. 4, pp. 312–313, 1998. View at Scopus
  12. A. B. Lowenfels, P. Maisonneuve, G. Cavallini, et al., “Pancreatitis and the risk of pancreatic cancer: International Pancreatitis Study Group,” The New England Journal of Medicine, vol. 328, no. 20, pp. 1433–1437, 1993.
  13. C. Fenoglio-Preiser, F. Carneiro, P. Correa, et al., “Gastric carcinoma,” in World Health Organization Classification of Tumors; Pathology and Genetics of Tumors of the Digestive System, S. R. Hamilton and L. A. Aaltonen, Eds., pp. 37–52, IARC Press, Lyon, France, 2000.
  14. C. N. Chen, J. J. Lin, J. J. W. Chen et al., “Gene expression profile predicts patient survival of gastric cancer after surgical resection,” Journal of Clinical Oncology, vol. 23, no. 29, pp. 7286–7295, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Zou, “Regulatory T cells, tumour immunity and immunotherapy,” Nature Reviews Immunology, vol. 6, no. 4, pp. 295–307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. X. C. Wang, J. Q. Zhang, Y. Q. Shen, F. Q. Miao, and W. Xie, “Loss of heterozygosity at 6p21.3 underlying HLA class I downregulation in gastric cancer,” Journal of Experimental and Clinical Cancer Research, vol. 25, no. 1, pp. 115–119, 2006. View at Scopus
  17. C. C. Chang, M. Campoli, and S. Ferrone, “HLA class I defects in malignant lesions: what have we learned?” Keio Journal of Medicine, vol. 52, no. 4, pp. 220–229, 2003. View at Scopus
  18. A. Takahashi, K. Kono, H. Amemiya, H. Iizuka, H. Fujii, and Y. Matsumoto, “Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer,” Clinical Cancer Research, vol. 7, no. 1, pp. 74–80, 2001. View at Scopus
  19. G. P. Dunn, L. J. Old, and R. D. Schreiber, “The three Es of cancer immunoediting,” Annual Review of Immunology, vol. 22, pp. 329–360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. Q. Gao, S. J. Qiu, J. Fan et al., “Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection,” Journal of Clinical Oncology, vol. 25, no. 18, pp. 2586–2593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. G. P. Dunn, L. J. Old, and R. D. Schreiber, “The immunobiology of cancer immunosurveillance and immunoediting,” Immunity, vol. 21, no. 2, pp. 137–148, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Asano, M. Toda, N. Sakaguchi, and S. Sakaguchi, “Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation,” Journal of Experimental Medicine, vol. 184, no. 2, pp. 387–396, 1996. View at Scopus
  24. S. Sakaguchi, N. Sakaguchi, J. Shimizu et al., “Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance,” Immunological Reviews, vol. 182, pp. 18–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Somasundaram, L. Jacob, R. Swoboda et al., “Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β,” Cancer Research, vol. 62, no. 18, pp. 5267–5272, 2002. View at Scopus
  26. M. Awwad and R. J. North, “Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells,” Cancer Research, vol. 49, no. 7, pp. 1649–1654, 1989. View at Scopus
  27. E. Y. Woo, C. S. Chu, T. J. Goletz et al., “Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer,” Cancer Research, vol. 61, no. 12, pp. 4766–4772, 2001. View at Scopus
  28. E. Y. Woo, H. Yeh, C. S. Chu et al., “Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation,” Journal of Immunology, vol. 168, no. 9, pp. 4272–4276, 2002. View at Scopus
  29. U. K. Liyanage, T. T. Moore, H. G. Joo et al., “Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma,” Journal of Immunology, vol. 169, no. 5, pp. 2756–2761, 2002. View at Scopus
  30. F. Ichihara, K. Kono, A. Takahashi, H. Kawaida, H. Sugai, and H. Fujii, “Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers,” Clinical Cancer Research, vol. 9, no. 12, pp. 4404–4408, 2003. View at Scopus
  31. F. Pagès, A. Berger, M. Camus et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” New England Journal of Medicine, vol. 353, no. 25, pp. 2654–2666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Ishigami, S. Natsugoe, K. Tokuda, et al., “Prognostic value of intratumoral natural killer cells in gastric carcinoma,” Cancer, vol. 88, no. 3, pp. 577–583, 2000.
  33. Y. Maehara, S. Tomisaki, S. Oda, et al., “Lymph node metastasis and relation to tumor growth potential and local immune response in advanced gastric cancer,” International Journal of Cancer, vol. 74, no. 2, pp. 224–228, 1997.
  34. K. Fukuda, S. Tsujitani, Y. Maeta, K. Yamaguchi, M. Ikeguchi, and N. Kaibara, “The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma,” Gastric Cancer, vol. 5, no. 4, pp. 220–227, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. G. P. Dunn, L. J. Old, and R. D. Schreiber, “The immunobiology of cancer immunosurveillance and immunoediting,” Immunity, vol. 21, no. 2, pp. 137–148, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. H. E. Lee, S. W. Chae, Y. J. Lee et al., “Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer,” British Journal of Cancer, vol. 99, no. 10, pp. 1704–1711, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. A. Alpizar, B. Chain, M. K. Collins et al., “Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies,” Cancer Immunology, Immunotherapy, vol. 60, no. 8, pp. 1127–1135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. S. C. Gilbert, “T-cell-inducing vaccines—what's the future,” Immunology, vol. 135, no. 1, pp. 19–26, 2012.
  39. A. Jorritsma, T. N. M. Schumacher, and B. A. G. John Haanen, “Immunotherapeutic strategies: the melanoma example,” Immunotherapy, vol. 1, no. 4, pp. 679–690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. J. Kim, J. Lim, J. S. Kang et al., “Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells,” Archives of Pharmacal Research, vol. 33, no. 11, pp. 1789–1795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Sangiolo, “Cytokine induced killer cells as promising immunotherapy for solid tumors,” Journal of Cancer, vol. 2, pp. 363–368, 2011.
  42. T. Hoshino, N. Seki, M. Kikuchi, et al., “HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer,” International Journal of Cancer, vol. 70, no. 6, pp. 631–638, 1997.
  43. K. Kono, Y. Rongcun, J. Charo, et al., “Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes,” International Journal of Cancer, vol. 78, no. 2, pp. 202–208, 1998.
  44. D. L. Guo, M. Dong, L. Wang, L. P. Sun, and Y. Yuan, “Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori-associated gastric diseases,” World Journal of Gastroenterology, vol. 8, no. 6, pp. 1009–1013, 2002. View at Scopus
  45. K. Wu, Y. Nie, C. Guo, Y. Chen, J. Ding, and D. Fan, “Molecular basis of therapeutic approaches to gastric cancer,” Journal of Gastroenterology and Hepatology, vol. 24, no. 1, pp. 37–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Jiang, N. Xu, C. Wu et al., “Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells,” Anticancer Research, vol. 26, no. 3, pp. 2237–2242, 2006. View at Scopus
  47. C. Wu, J. Jiang, L. Shi, and N. Xu, “Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer,” Anticancer Research, vol. 28, no. 6, pp. 3997–4002, 2008. View at Scopus
  48. S. Sun, X. M. Li, X. D. Li, and W. S. Yang, “Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines,” Cancer Biotherapy and Radiopharmaceuticals, vol. 20, no. 2, pp. 173–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. F. G. Gao, V. Khammanivong, W. J. Liu, G. R. Leggatt, I. H. Frazer, and G. J. P. Fernando, “Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell,” Cancer Research, vol. 62, no. 22, pp. 6438–6441, 2002. View at Scopus
  50. M. M. D'Elios and M. P. Bergman, “Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 104918, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Amedei, E. Niccolai, C. Della Bella et al., “Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma,” Cancer Immunology, Immunotherapy, vol. 58, no. 11, pp. 1819–1830, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Maggi, V. Santarlasci, F. Liotta et al., “Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals,” Journal of Allergy and Clinical Immunology, vol. 120, no. 2, pp. 429–436, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Nishikawa, T. Kato, K. Tanida et al., “CD4+CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 19, pp. 10902–10906, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. C. Baecher-Allan and D. E. Anderson, “Immune regulation in tumor-bearing hosts,” Current Opinion in Immunology, vol. 18, no. 2, pp. 214–219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Cho, M. Miyamoto, K. Kato et al., “CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma,” Cancer Research, vol. 63, no. 7, pp. 1555–1559, 2003. View at Scopus
  56. P. Yu and Y. X. Fu, “Tumor-infiltrating T lymphocytes: friends or foes?” Laboratory Investigation, vol. 86, no. 3, pp. 231–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. F. A. Sinicrope, R. L. Rego, S. M. Ansell, K. L. Knutson, N. R. Foster, and D. J. Sargent, “Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma,” Gastroenterology, vol. 137, no. 4, pp. 1270–1279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. R. P. Petersen, M. J. Campa, J. Sperlazza et al., “Tumor infiltrating FOXP3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients,” Cancer, vol. 107, no. 12, pp. 2866–2872, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Fu, D. Xu, Z. Liu et al., “Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients,” Gastroenterology, vol. 132, no. 7, pp. 2328–2339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. T. J. Curiel, G. Coukos, L. Zou et al., “Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival,” Nature Medicine, vol. 10, no. 9, pp. 942–949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. G. J. Bates, S. B. Fox, C. Han et al., “Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse,” Journal of Clinical Oncology, vol. 24, no. 34, pp. 5373–5380, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. G. Perrone, P. A. Ruffini, V. Catalano et al., “Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer,” European Journal of Cancer, vol. 44, no. 13, pp. 1875–1882, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Haas, A. Dimmler, W. Hohenberger, G. G. Grabenbauer, G. Niedobitek, and L. V. Distel, “Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia,” BMC gastroenterology, vol. 9, article 65, 2009. View at Scopus
  64. Y. Mizukami, K. Kono, Y. Kawaguchi et al., “Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer,” British Journal of Cancer, vol. 98, no. 1, pp. 148–153, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Ladoire, L. Arnould, L. Apetoh et al., “Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating Foxp3+ regulatory T cells,” Clinical Cancer Research, vol. 14, no. 8, pp. 2413–2420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. F. Liotta, M. Gacci, F. Frosali et al., “Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma,” BJU International, vol. 107, no. 9, pp. 1500–1506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. S. A. Siddiqui, X. Frigola, S. Bonne-Annee et al., “Tumor-infiltrating Foxp3CD4+CD25+ T cells predict poor survival in renal cell carcinoma,” Clinical Cancer Research, vol. 13, no. 7, pp. 2075–2081, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. Z. Shen, S. Zhou, Y. Wang et al., “Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer,” Journal of Cancer Research and Clinical Oncology, vol. 136, no. 10, pp. 1585–1595, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. X. L. Yuan, L. Chen, T. T. Zhang et al., “Gastric cancer cells induce human CD4+Foxp3+ regulatory T cells through the production of TGF-β1,” World Journal of Gastroenterology, vol. 17, no. 15, pp. 2019–2027, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Mizukami, K. Kono, Y. Kawaguchi et al., “CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer,” International Journal of Cancer, vol. 122, no. 10, pp. 2286–2293, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. L. S. Shen, J. Wang, D. F. Shen et al., “CD4+CD25+CD127low/ regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression,” Clinical Immunology, vol. 131, no. 1, pp. 109–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. C. T. Weaver, L. E. Harrington, P. R. Mangan, M. Gavrieli, and K. M. Murphy, “Th17: an effector CD4 T cell lineage with regulatory T cell ties,” Immunity, vol. 24, no. 6, pp. 677–688, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Bettelli, M. Oukka, and V. K. Kuchroo, “TH-17 cells in the circle of immunity and autoimmunity,” Nature Immunology, vol. 8, no. 4, pp. 345–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. C. M. Wilke, K. Bishop, D. Fox, and W. Zou, “Deciphering the role of Th17 cells in human disease,” Trends Immunology, vol. 32, no. 12, pp. 603–611, 2011.
  75. B. F. Zamarron and W. Chen, “Dual roles of immune cells and their factors in cancer development and progression,” International Journal of Biological Sciences, vol. 7, no. 5, pp. 651–658, 2011. View at Scopus
  76. I. Kryczek, S. Wei, L. Zou et al., “Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment,” Journal of Immunology, vol. 178, no. 11, pp. 6730–6733, 2007. View at Scopus
  77. Y. Miyahara, K. Odunsi, W. Chen, G. Peng, J. Matsuzaki, and R. F. Wang, “Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 40, pp. 15505–15510, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. X. Su, J. Ye, E. C. Hsueh, Y. Zhang, D. F. Hoft, and G. Peng, “Tumor microenvironments direct the recruitment and expansion of human Th17 cells,” Journal of Immunology, vol. 184, no. 3, pp. 1630–1641, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. J. P. Zhang, J. Yan, J. Xu et al., “Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients,” Journal of Hepatology, vol. 50, no. 5, pp. 980–989, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. M. G. Alexandrakis, C. A. Pappa, S. Miyakis et al., “Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma,” European Journal of Internal Medicine, vol. 17, no. 6, pp. 412–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. C. Wu, S. Wang, F. Wang et al., “Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia,” Clinical and Experimental Immunology, vol. 158, no. 2, pp. 199–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. I. Kryczek, M. Banerjee, P. Cheng et al., “Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments,” Blood, vol. 114, no. 6, pp. 1141–1149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. Z. Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell, “Malignant B cells skew the balance of regulatory T cells and T H17 cells in B-cell non-Hodgkin's lymphoma,” Cancer Research, vol. 69, no. 13, pp. 5522–5530, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Horlock, B. Stott, P. J. Dyson et al., “The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer,” British Journal of Cancer, vol. 100, no. 7, pp. 1061–1067, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. K. S. Sfanos, T. C. Bruno, C. H. Maris et al., “Phenotypic analysis of prostate-infiltrating lymphocytes reveals T H17 and Treg skewing,” Clinical Cancer Research, vol. 14, no. 11, pp. 3254–3261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Tartour, F. Fossiez, I. Joyeux et al., “Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice,” Cancer Research, vol. 59, no. 15, pp. 3698–3704, 1999. View at Scopus
  87. F. Benchetrit, A. Ciree, V. Vives et al., “Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism,” Blood, vol. 99, no. 6, pp. 2114–2121, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. H. Takahashi, M. Numasaki, M. T. Lotze, and H. Sasaki, “Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells,” Immunology Letters, vol. 98, no. 2, pp. 189–193, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Numasaki, J. I. Fukushi, M. Ono et al., “Interleukin-17 promotes angiogenesis and tumor growth,” Blood, vol. 101, no. 7, pp. 2620–2627, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. K. A. Charles, H. Kulbe, R. Soper et al., “The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans,” Journal of Clinical Investigation, vol. 119, no. 10, pp. 3011–3023, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. D. M. Kuang, C. Peng, Q. Zhao, Y. Wu, M. S. Chen, and L. Zheng, “Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells,” Hepatology, vol. 51, no. 1, pp. 154–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. P. A. Antony, C. A. Piccirillo, A. Akpinarli et al., “CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells,” Journal of Immunology, vol. 174, no. 5, pp. 2591–2601, 2005. View at Scopus
  93. K. L. Knutson, M. L. Disis, and L. G. Salazar, “CD4 regulatory T cells in human cancer pathogenesis,” Cancer Immunology, Immunotherapy, vol. 56, no. 3, pp. 271–285, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Benatar, M. Y. Cao, Y. Lee et al., “Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors,” Cancer Immunology, Immunotherapy, vol. 57, no. 12, pp. 1757–1769, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Benatar, M. Y. Cao, Y. Lee et al., “IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo,” Cancer Immunology, Immunotherapy, vol. 59, no. 6, pp. 805–817, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. J. A. Kyte, S. Trachsel, B. Risberg, P. thor Straten, K. Lislerud, and G. Gaudernack, “Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination,” Cancer Immunology, Immunotherapy, vol. 58, no. 10, pp. 1609–1626, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. N. Martin-Orozco, P. Muranski, Y. Chung et al., “T helper 17 cells promote cytotoxic T cell activation in tumor immunity,” Immunity, vol. 31, no. 5, pp. 787–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. E. Alvarez, E. Moga, J. Barquinero, J. Sierra, and J. Briones, “Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response,” Gene Therapy, vol. 17, no. 4, pp. 469–477, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. E. Derhovanessian, V. Adams, K. Hähnel et al., “Pretreatment frequency of circulating IL-17+CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients,” International Journal of Cancer, vol. 125, no. 6, pp. 1372–1379, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. B. Zhang, G. Rong, H. Wei et al., “The prevalence of Th17 cells in patients with gastric cancer,” Biochemical and Biophysical Research Communications, vol. 374, no. 3, pp. 533–537, 2008. View at Publisher · View at Google Scholar · View at Scopus
  101. J. L. Gnerlich, J. B. Mitchem, J. S. Weir, et al., “Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer,” The Journal of Immunology, vol. 185, no. 7, pp. 4063–4071, 2010.
  102. M. D. Sharma, D. Y. Hou, Y. Liu, and P. A. Koni, “Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes,” Blood, vol. 113, no. 24, pp. 6102–6111, 2009.
  103. P. Muranski, A. Boni, and P. A. Antony, “Tumor-specific Th17-polarized cells eradicate large established melanoma,” Blood, vol. 112, no. 23, pp. 362–673, 2008.
  104. Z. J. Ye, Q. Zhou, Y. Y. Gu, et al., “Generation and differentiation of IL-17–producing CD4+ T cells in malignant pleural effusion,” The Journal of Immunology, vol. 185, no. 10, pp. 6348–6354, 2010.